The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10B | Blood glucose lowering drugs, excl. insulins | |
4
|
A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | |
5
|
A10BK06 |
| Active Ingredient |
|---|
|
Sotagliflozin is an inhibitor of SGLT2 and SGLT1. Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium which may influence several physiological functions such as lowering both pre-and afterload of the heart and downregulating sympathetic activity. Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea. The mechanism for sotagliflozin’s cardiovascular benefits has not been established. |
| Document | Type | Information Source | |
|---|---|---|---|
| INPEFA Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ZYNQUISTA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |